Health Policy

Function

The Working Group on Health Policy deals with business and political parameters, ranging from licensing, paths to reimbursement, market access and care to billing for biopharmaceutical products. More broadly, its work also involves analysing the business policy and health economy policy issues of the legal parameters for Germany as a biotech location.

Members

Co-ordinators

Prof. Dr. Helga Rübsamen-Schaeff AiCuris GmbH & Co. KG
Prof. Dr. med. Niels Riedemann InflaRx GmbH

Experts from the following companies

Barbara Behle Miltenyi Biotec GmbH
Dr. Dirk Bernhardt DiBe-Consulting
Dr. Klaus Dembowsky amcure GmbH
Dr. Edgar Fenzl FGK Clinical Research GmbH
Dr. Christian Fulda Jones Day
Thomas Gabrielczyk BIOCOM
Dr. Peter Heinrich Sinfonie Life Science Management GmbH
Stefan Kinner Vertex Pharmaceuticals (Germany) GmbH
Dr. Claus Kusnierz-Glaz PricewaterhouseCoopers AG WPG
Dr. Alexander Natz EUCOPE - European Confederation of Pharmaceutical Entrepreneurs AISBL
Dr. Martin Pöhlchen Sinfonie Life Science Management GmbH
Dr. Klaus Maleck TETEC AG
Prof. Dr. med Niels Riedemann InflaRx GmbH
Jasper Romahn NDA Regulatory Service GmbH
Prof. Dr. Helga Rübsamen-Schaeff AiCuris Anti-infective Cures GmbH
Hildegard Schmatz NDA Regulatory Service GmbH
Dr. Julia Schüler BioMedServices
Dr. Maren von Fritschen EUCOPE - European Confederation of Pharmaceutical Entrepreneurs AISBL
Piet Weinreich Osborne Clarke
André Zöller Vertex Pharmaceuticals (Germany) GmbH